- Shares of Annovis Bio (NYSE:ANVS) greater than doubled in worth on Tuesday after the corporate stated its lead asset, buntanetap, was discovered to be secure and efficient in bettering the bodily and cognitive features of sufferers with early Parkinson’s illness.
- Updating information from its Section 3 PD trial, Annovis (ANVS) stated buntanetap, designed to focus on neurotoxic proteins, maintained cognition in the whole affected person inhabitants at 10 and 20 mg doses, whereas these on placebo deteriorated all through the research.
- At 20 mg, the research drug “confirmed vital enchancment in cognition in comparison with placebo,” the corporate added.
- With a constant tolerability profile throughout early and superior PD sufferers, buntanetap led to statistically vital enhancements in all major and secondary endpoints in particular subgroups, in keeping with Annovis Bio (ANVS).
- The corporate has scheduled a webcast at 4:30 PM ET on July 2 to discuss additional results.